Stock Groups

Pfizer to buy RSV drug developer ReViral for up to $525 million -Breaking

[ad_1]

© Reuters. FILEPHOTO: This illustration, taken September 29th 2021, shows a 3D-printed logo of Pfizer placed next to medicines made by the same manufacturer. REUTERS/Dado Ruvic

(Reuters) -Pfizer Inc announced Thursday that it will buy ReViral Ltd, a privately held company, in a transaction worth up to $525 million. This deal includes milestone payments and allows for access to drugs to combat the respiratory syncytialvirus (RSV).

Reviral, a London-based company, has four RSV treatments in the pipeline. Two of these are currently in middle-stage research, and one is its lead product candidate sisunatovir.

This deal is the second U.S.-based drugmaker to acquire drugs in less than six month. Pfizer Arena Pharmaceuticals, which was purchased by the NYSE in December at a value of $6.7Billion, has been added to its portfolio as a promising treatment option for bowel disease.

RSV, a common viral respiratory disease that can cause symptoms similar to a cold, is quite serious. This is the most common form of pneumonia among children and elderly.

GlobalData analytics estimates the RSV Prevention Market will increase 140% to $6.3 Billion by 2030, from 2020. It is a profitable market that drugmakers worldwide can tap into.

[ad_2]